[18F]-Fluorodeoxyglucose Positron Emission Tomography for In Vivo Assessment of Glucose Metabolism in Pheochromoctyoma and Paraganglioma

Recruiting

• Conditions: adrenal tumours; 10029112; 10014710

• Registration Number: NL-OMON38518
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 25

Inclusion Criteria

- Age >= 18 years, no upper limit
- Suspected diagnosis of benign PCC or PGL:
1. Biochemically proven by elevated plasma and/or urinary (nor)metanephrines
2. Anatomically substrate; localization of an (extra)-adrenal tumor by conventional anatomical (MRI/CT) imaging
- Regardless of the genetic status (sporadic or hereditary)
- Planned for surgical resection (adrenalectomy or extra-adrenal tumor resection)
- Size tumor at least 1 cm in smallest diameter (as determined by conventional imaging)

Exclusion Criteria

- Malignant PPGL, i.e. presence of lesions on imaging studies suggestive of distant metastasis
- No initial CT or MRI available
- Contra-indication for surgery:
o Based on (biological) age, cardiovascular risk factors, performance status or other co-morbidity as decided by a multidisciplinary team including medical endocrinologist, urologists, radiologists, pathologists and nuclear medicine physicians.
- Contra-indication for dynamic FDG-PET/CT
o Diabetes mellitus or fasted glucose level >= 8.0 mmol.L-1
o Pregnancy
o Breast-feeding
o Sever claustrophobia
- Interval between dynamic FDG-PET/CT and surgery more than 60 days
- Incapability to adhere to study protocol
- Inability to give informed consent (e.g. psychiatric illness)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To increase insight in the in vivo glucose metabolism in PPGL by performing<br /><br>pharmacokinetic analyses of dynamic FDG-PET/CT scanning. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- To assess the genotypic specific differences in glucose metabolism across<br /><br>sporadic and hereditary PPGLs and to evaluate whether higher FDG-PET/CT SUV<br /><br>observed in SDHx and VHL-related PPGL is a reflection of an increased FDG<br /><br>uptake and/or metabolism as a reflection the Warburg effect.<br /><br>- To investigate whether quantitative dynamic FDG-PET/CT parameters correlate<br /><br>with tumor histology and tissue markers of glucose metabolism (GLUT-1, GLUT-3,<br /><br>HK-2, HK-3 and MCT-4) and vascularity (VEGF, CD34).</p><br>